News
The tariff threat come just a few days after the White House sent letters to major drugmakers demanding slashed prices for US ...
Investing in clinical-stage biotechnology always carries significant risks, and aTyr is no exception. The company reported a ...
StockStory.org on MSN4h
ANI Pharmaceuticals (ANIP) Q2 Earnings: What To ExpectSpecialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) will be reporting earnings this Friday before the bell.
The FDA accepted a supplemental application for Breyanzi to treat adults with relapsed or refractory marginal zone lymphoma ...
Type II cryoglobulinemic vasculitis in patients with Sjögren disease is associated with nearly a sevenfold increased risk for lymphoma and death in a study.
In 2017, Megan Wanzo was pursuing health care ethics, uncertain but hopeful that she was on the right path, when she attended ...
At first glance, Pfizer delivered a strong Q2 and upped its 2025 full-year EPS guidance. Click here to find out why I rate ...
Contineum Therapeutics has pumped the brakes on two projects, freeing up resources to go full speed ahead in its pursuit of Bristol Myers Squibb in idiopathic pulmonary fibrosis.
After beating AstraZeneca’s Calquence in quarterly revenue for the first time at the end of 2024, BeOne Medicines’ Brukinsa ...
14h
The Manila Times on MSNPfizer raises 2025 profit forecastPFIZER said its full-year profit should benefit from cost cuts across its research and manufacturing operations after posting higher-than-expected second-quarter earnings on Tuesday.
BioNTech also laid off 63 employees in June in conjunction with the discontinuation of its cell therapy manufacturing ...
One piece of good news: When we expanded our stock screen to include solid companies with a yield of at least 4% rather than 5%, Omnicom, with a dividend yield of 4.1%, made the new list. Interpublic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results